Morphological changes caused by injections of 5-HT in animals and man

  • R. S. Stacey
Part of the Handbook of Experimental Pharmacology/Handbuch der experimentellen Pharmakologie book series (HEP, volume 19)

Abstract

The rapid inactivation of 5-HT makes it possible to give large doses to animals over many weeks ; moreover tolerance rapidly develops and near lethal doses can be quickly increased. Hedinger and Veraguth (1962) for example, using rats, started with daily intraperitoneal doses of 1 to 15 mg base/kg and were able to increase the dose to over 500 mg base/kg in 20 days. Similarly with guinea-pigs, starting with a dose of 40 mg base/kg i.p., the dose could be doubled every 5 days until 320 mg base/kg was being given. However when large doses are given, whether singly or repeatedly, morphological changes develop in many organs.

Keywords

Sponge Oestradiol Adrenaline Prolactin Atropine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Angrist, A., M. Oka, and K. Nakao: Failure to produce right-sided valve lesions by intra-hepatic pellets of 5-hydroxytryptophan. Fed. Proc. 21, 95 (1962).Google Scholar
  2. Archer, R. K.: Eosinophil leucocytes and their reactions to histamine and 5-hydroxytrypt-amine. J. Path. Bact. 78, 95–103 (1959).PubMedCrossRefGoogle Scholar
  3. Asboe-Hansen, G., and O. Wegelius: Serotonin and connective tissue. Nature (Lond.) 178, 262 (1956).CrossRefGoogle Scholar
  4. Ballerini, G., e T. Cantelli: Piastrinosi sperimentale da 5-idrossitriptamma. Boll. Soc. ital. Ematol. 3, 405–408 (1955).Google Scholar
  5. Baumgartner, H. R., A. Studer u. K. Reber: Über Methoden zur Erzeugung experimenteller Thrombosen am Kaninchenohr und die Bedeutung von 5-Hydroxytryptamin bei deren Entstehung. Thrombos. Diathes. haemorrh. (Stuttg.) 9, 48–511 (1963).Google Scholar
  6. Blackmax, J. G., D. S. Campion, and F. M. Fastier: Mechanism of action of reserpine in producing gastric haemorrhage and erosion in the mouse. Brit. J. Pharmacol. 14, 112–116 (1959).Google Scholar
  7. Boccabella, A. V., E. D. Salgado, and E.A. Alger: Testicular function and histology following serotonin administration. Endocrinology 71, 827–837 (1962).CrossRefGoogle Scholar
  8. Boseila, A.-W. A.: Influence of heparin and serotonin on basophil leucocytes of rabbit blood. Experientia (Basel) 15, 343–344 (1959).CrossRefGoogle Scholar
  9. Brosman, S. A., P. F. Bradford, and F. W. Hughes: Modification of renal lesions produced by 5-hydroxytryptamine (serotonin). Amer. J. Clin. Path. 32, 457–464 (1959).Google Scholar
  10. Carlier, J., G. Lejeune-Ledant et Ch. Keil: 5-Hydroxytryptamine, lésions pulmonaires et pression artérielle pulmonaire. Med. exp. (Basel) 1, 72–77 (1959).CrossRefGoogle Scholar
  11. Cenacchi, G. C., E. Bergami, D. Cavazzoni e L. Rosa: Effetto eosinopenico délia 5-ossitript-amina. Folia allerg. (Roma) 6, 14–24 (1959).Google Scholar
  12. Davidson, J., A. Sjoerdsma, L. N. Loomis, and S. Udenfriend: Studies with the serotonin precursor, 5-hydroxytryptophan, in experimental animals and man. J. clin. Invest. 36, 1594–1599 (1957).PubMedCrossRefGoogle Scholar
  13. Eder, M., u. A. Schauer: Morphologische und experimentelle Untersuchungen zur Fibro-sierung beim Carcinoid. Beitr. path. Anat. 121, 375–405 (1959).Google Scholar
  14. Erspamer, V.: Pharmocology of indolealkylamines. Pharmacol. Rev. 6, 425–487 (1954a).PubMedGoogle Scholar
  15. Erspamer, V.: Observations on the fate of oral 4-HTP in man. Experientia (Basel) 17, 351–352 (1961a).CrossRefGoogle Scholar
  16. Erspamer, V.: Recent research in the field of 5-hydroxytryptamine and related indolealkylamines. Fortschr. Arzneimittelforsch. 3, 151–367 (1961b).PubMedGoogle Scholar
  17. Feldberg, W., and A.N. Smith: Release of histamine by tryptamine and 5-hydroxytryptamine. Brit. J. Pharmacol. 8, 406–411 (1953).PubMedGoogle Scholar
  18. Ferrata. A., e G. A. Cappelletti: Sulla trombocitosi da serotonina. Haematologica 44, 501–512 (1959).PubMedGoogle Scholar
  19. Fiore-Donati, L. and V. Erspamer: Studies on the nephrotoxicity of 5-hydroxytryptamine (enteramine) in the rat. Amer. J. Path. 33, 895–917 (1957).PubMedGoogle Scholar
  20. Gottlieb, L. S., S. A. Broitman, J. J. Vitale, and N. Zamcheck: Failure of endogenous serotonin to produce lesions of the carcinoid syndrome. Studies in mouse mastocytoma. Arch. Path. 69, 77–81 (1960).PubMedGoogle Scholar
  21. Haverback, B. J. and D. F. Bogdanski: Gastric mucosal erosion in the rat following administration of the serotonin precursor, 5-hydroxytryptophan. Proc. Soc. exp. Biol. (N.Y.) 95, 392–393 (1957).Google Scholar
  22. Hedinger, C.: Hodenveränderungen bei Ratten und Meerschweinchen nach Serotonin-injektionen. Path, et Microbiol. (Basel) 26, 325–329 (1963).Google Scholar
  23. Hedinger, C., u. H. Langemann: Ausgesprochene Thrombocytose bei Ratten unter Behandlung mit 5-Oxytryptamin. Schweiz. med. Wschr. 85, 368–370 (1955a).PubMedGoogle Scholar
  24. Hedinger, C., u. H. Langemann: Nierenschädigungen mit Rindennekrosen bei Ratten unter Behandlung mit 5-Oxy-tryptamine. Schweiz. med. Wschr. 85, 541–544 (1955b).PubMedGoogle Scholar
  25. Hedinger, C., u. F. Veraguth: Magengeschwüre bei Ratten unter Behandlung mit 5-Hydroxytryptamin. Schweiz. med. Wschr. 87, 1175–1176 (1957).PubMedGoogle Scholar
  26. Hedinger, C., u. F. Veraguth: Magengeschwüre bei Ratten und Meerschweinchen nach intraperitonealer Injektion von 5-Hydroxytryptamin (Serotonin). Z. ges. exp. Med. 136, 64–77 (1962).PubMedCrossRefGoogle Scholar
  27. Honour, A. J., and J. R. A. Mitchell: Platelet clumping in vivo. Nature (Lond.) 197, 1019–1020 (1963).CrossRefGoogle Scholar
  28. Huser, H. J., C. Sandri u. C. Hedinger: Thrombozytose bei Meerschweinchen unter massiver Behandlung mit 5-Hydroxytryptamin (Serotonin). Klin. Wschr. 37, 660–662 (1959).PubMedCrossRefGoogle Scholar
  29. Jasmin, G., and P. Bois: Effect of various agents on the development of kidney infarcts in rats treated with serotonin. Lab. Invest. 9, 503–515 (1960).PubMedGoogle Scholar
  30. Kim, K. S., and P. A. Shore: Mechanism of action of reserpine and insulin on gastric amines and gastric secretion and the effect of monoamine oxidase inhibition. J. Pharmacol. exp. Ther. 141, 321–325 (1963).PubMedGoogle Scholar
  31. Kwaan, H. C., R. Lo, and A. J. S. Mcfadzean: On the lysis of thrombi experimentally produced within veins. Brit. J. Haemat. 4, 51–62 (1958).PubMedCrossRefGoogle Scholar
  32. LA Barre, J.: A propos de la pathogénèse de l’ulcère gastrique post réserpinique. C. R. Soc. Biol. (Paris) 153, 364–366 (1959).Google Scholar
  33. Langemann, H., u. J. Kägi: Oxytryptamin-und Oxyindolessigsäurebestimmungen bei einem Fall von Carcinoidsyndrom, nebst einigen anderen Untersuchungen über Oxytryptamin. Klin. Wschr. 34, 237–241 (1956).PubMedCrossRefGoogle Scholar
  34. Leusen, L., E. Lacroix, and G. Demeester: Influence of iproniazid on formation of gastric ulcères by reserpine in the rat. Experientia (Basel) 15, 73 (1959).CrossRefGoogle Scholar
  35. Levis, S., et J. Beersaerts: E’tude de l’activité de la chlorbenzoxamine dans quelques types d’ulcères expérimentaux. Pharmacodyn. 126, 359–364 (1960).Google Scholar
  36. Lindsay, D., E. Poulson, and J. M. Robson: The effect of 5-HT on pregnancy. J. Endocr. 26, 85–96 (1963).CrossRefGoogle Scholar
  37. Macdonald, R. A.: Pathogenesis of lesions induced by serotonin: nutritional, vascular, auto-radiographic and comparative studies using epinephrine. Amer. J. Path. 35, 297–313 (1959).PubMedGoogle Scholar
  38. Macdonald, R. A., and S. L. Robbins: Dermal fibrosis following subcutaneous injections of serotonin crea-tinine sulphate. Proc. Soc. exp. Biol. (N.Y.) 97, 334–337 (1958b)., and G. K. MALLORY: Morphologic effects of serotonin (5-hydroxytryptamine). Arch. Path. 65, 369-377 (1958a).Google Scholar
  39. Macdonald, R. A.: R. Schmid, T. R. Hakala, and G. K. Mallory: Effect of serotonin upon liver cells of young rats. Proc. Soc. exp. Biol. (N.Y.) 101, 83–86 (1959).Google Scholar
  40. Meites, J., C. S. Nicoll, and P. K. Talwalker: Effect of reserpine and serotonin on milk secretion and mammary growth in the rat. Proc. Soc. exp. Biol. (N.Y.) 101, 563–365 (1959).Google Scholar
  41. Meites, J., P. K. Talwalker, and C. S. Nicoll: Induction of mammary growth and lactation in rabbits with epinephrine, acetylcholine and serotonin. Proc. Soc. exp. Biol (N.Y.) 104, 192–194 (1960).Google Scholar
  42. Morlunghi, C. e P. Romeo: Effetti della somministrazione cronica della 5-idrossitriptamina (serotonina) sulla coniglia gravida. Arch. Ostet. Ginec. 66, 155–173 (1961).PubMedGoogle Scholar
  43. Ntkodijevic, B., and T. Trajkov: Mechanism of ulcerogenic action of 5-hydroxytryptamine in rat’s stomach. Biochem. Pharmacol. 8, 169 (1961).CrossRefGoogle Scholar
  44. Ntkodijevic, B., and S. Yanov: The influence of thenalidine on reserpine-and serotonin-induced gastric ulcers in rats. Experientia (Basel) 16, 464–465 (1960).CrossRefGoogle Scholar
  45. Owens, F. J., and G. M. C. Masson: Effects of amine liberators on gastric secretions in the rat. J. Lab. clin. Med. 53, 932–933 (1958).Google Scholar
  46. Page, E. W., and M. B. Glendening: Production of renal cortical necrosis with serotonin (5-hydroxytryptamine). Amer. J. Med. 19, 285 (1955).CrossRefGoogle Scholar
  47. Poulson, E., M. Botros, and J. M. Robson: Effect of 5-hydroxytryptamine and iproniazid on pregnancy. Science 181, 1101–1102 (1960).CrossRefGoogle Scholar
  48. Poulson, E., J. M. Robson. and F. M. Sullivan: Teratogenic effect of 5-HT in mice. Science 141, 717–718 (1963b).PubMedCrossRefGoogle Scholar
  49. Reddy. D. V., F. H. Adams, and C. Baird: Teratogenic effects of serotonin. J. Pediat. 63, 394–401 (1963).PubMedCrossRefGoogle Scholar
  50. Robertson, J. I. S., W. S. Peart, and T. M. Andrews: The mechanism of facial flushes in the carcinoid syndrome. Quart. J. Med. 31, 103–123 (1962).PubMedGoogle Scholar
  51. Robson, J. M., and M. Botros: The effect of 5-hydroxytryptamine and of monoamine oxidase inhibitors on sexual maturity. J. Endocr. 22, 165–175 (1961).PubMedCrossRefGoogle Scholar
  52. Robson, J. M., and F. M. Sullivan: Mechanism of lethal action of 5-HT on the foetus. J. Endocr. 25, 553–554 (1963).PubMedCrossRefGoogle Scholar
  53. Rosa, L., G. C. Cenacchi et G. Bergami: Les variations numériques des éosinophiles circulants après injection d’antigène, d’histamine ou de 5-hvdroxvtrvptamine. Acta allerg. (Kbh.) 12, 427–431 (1958).Google Scholar
  54. Rossi, P., M. Stevenson, P. Khaksar. and S. Bellet: Coronary arteriosclerosis induced in young dogs bv prolonged intra-aortic infusion of serotonin. Circulat. Res. 9. 436–440 (1961).PubMedGoogle Scholar
  55. Rossi, P., and L. Zamboni: Pulmonary arteriosclerosis due to serotonin. Nature (Lond.) 181, 1216–1217 (1958).CrossRefGoogle Scholar
  56. Salgado, E. and D. M. Green. Renal necrosis induced in rats by serotonin. Amer. J. Physiol. 183, 657 (1955).Google Scholar
  57. Schauer, A., u. M. Eder: Der Fibrosierungsvorgano-beim Darmcarcinoid. Klin. Wschr. 37, 880–881 (1959).PubMedCrossRefGoogle Scholar
  58. Scherbel, A. L., R. L. Mckittrick, and W. A. Hawk: Lesions in rats caused by serotonin and histamine before and after amine oxidase inactivation and serotonin inhibition. J. clin. Invest. 39, 1025–1026 (1960).Google Scholar
  59. Serra, U. e K. Bruni: Comportamento delle piastrine e degli eosinofili circulante dopo somministrazione di 5-ossitriptamina in dose unica nel ratto. Folia endocr. (Roma) 10, 657–664 (1957).Google Scholar
  60. Steger, C.: Contributo sperimentale alla conoscenza dei rapporti esisteni tra carcinoidi intestinale e lesioni del cuore destro. Arch. ital. Chir. 84, 202 (1958).PubMedGoogle Scholar
  61. Steiner, F. A., u. C. Hedinger: Thromtozytose und Eosinopenie bei Ratten nach einmaliger 5-Oxytryptamininjektion. Experientia (Basel) 12, 109–111 (1956).CrossRefGoogle Scholar
  62. Steiner, F. A., R. E. Siebenmann, C. Sandri u. C. Hedinger: Thrombozytose und Eosinophilie bei Adrenalektomierten Ratten nach einmaliger 5-Hydroxytryptamininjection. Experientia (Basel) 13, 500–502 (1957).CrossRefGoogle Scholar
  63. Waugh, D., and M. J. Pearl: Serotonin-induced acute nephrosis and renal cortical necrosis in rats. Amer. J. Path. 36, 431–455 (1960).PubMedGoogle Scholar
  64. Wilhelmi. G.: Über die ulcerogene Wirkung von 5-Hvdroxytrvptamine am Rattenmagen und deren Beeinflussung durch verschiedene Pharmaca. Helv. physiol. acta. 15, C., 83–84 (1957).Google Scholar
  65. Wilhelmi. G., u. W. Schindler: Über die gastrotrope Wirkung von 5-Hydroxytryptamine (HTA), seiner Vorstufen und der entsprechenden Isomeren bei der Ratte. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak. 236 49–51 (1959).CrossRefGoogle Scholar
  66. Zbinden, G., A. Pletscher u. A. Studer: Beeinflussung experimenteller Magengeschwüre durch Reserpin, Tetrabenazin und Iproniazid (Marsilid). Schweiz. med. Wschr. 89, 289–291 (1959).PubMedGoogle Scholar
  67. Zbinden, G., A. Pletscher u. A. Studer: Bluteosinophile und Thrombocyten bei Hemmung der Monoaminoxydase und weiteren Einwirkungen auf den Katecholamin-und 5-Hvdroxytrvptamin-Stoffwechsel. Schweiz. med. Wschr. 88, 1067–1070 (1958).PubMedGoogle Scholar

Copyright information

© Springer-Verlag, Berlin · Heidelberg 1966

Authors and Affiliations

  • R. S. Stacey

There are no affiliations available

Personalised recommendations